WORCESTER, Mass., Aug. 7, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology announced today that enrollment of patients had begun for a new Phase I clinical trial employing a novel immunotherapeutic cancer vaccine being developed at Antigen Express, its wholly-owned subsidiary. The new trial will employ two immunotherapeutic vaccines designed to work in concert to activate the immune system to recognize and kill tumor cells in breast and ovarian cancer patients.
